Clinical Scorecard: Pleasantly Surprising Dry Eye Study Results
At a Glance
| Category | Detail |
|---|---|
| Condition | Dry Eye Disease |
| Key Mechanisms | Cyclosporine solution 0.09% improves symptoms and corneal staining in patients previously treated with cyclosporine emulsion 0.05%. |
| Target Population | Patients with dry eye uncontrolled on cyclosporine emulsion 0.05% for 3 months or longer. |
| Care Setting | Ophthalmology clinics, multicenter study. |
Key Highlights
- Significant decrease in total corneal fluorescein staining at weeks 4, 8, and 12.
- Improvement in modified Symptom Assessment in Dry Eye (mSANDE) scores.
- Efficacy observed across all age and sex subgroups.
- Cyclosporine 0.09% administered twice daily for 12 weeks.
- Study supports switching from cyclosporine 0.05% to 0.09% for better control.
Guideline-Based Recommendations
Diagnosis
- Evaluate patients with dry eye for treatment inadequacy on cyclosporine emulsion 0.05%.
Management
- Consider switching to cyclosporine solution 0.09% for patients inadequately controlled on cyclosporine 0.05%.
Monitoring & Follow-up
- Assess corneal fluorescein staining and mSANDE scores at baseline, 4, 8, and 12 weeks.
Risks
- Monitor for safety and tolerability; expected to be well tolerated.
Patient & Prescribing Data
Patients with dry eye disease uncontrolled on cyclosporine emulsion 0.05%.
Cyclosporine 0.09% shows statistically significant improvements in symptoms and staining.
Clinical Best Practices
- Switch to cyclosporine 0.09% for patients not responding to 0.05%.
- Monitor treatment response at regular intervals.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.